ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors targeting the ABL1 ATP-binding site, such as imatinib (Gleevec) and nilotinib (Tasigna), significantly improved the overall survival of CML patients (Kalmanti et al., 2015; Miura, 2015).